David Joseph Gaffin (EVP, CLO, Alkermes, Inc.) sold ~$68K of Alkermes plc
Scheduled in advanceTraded Apr 6, 2026 · Filed Apr 6, 2026
Alkermes's CLO, Alkermes, Inc. sold $70K of Alkermes shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$70,315
Shares × reported transaction price
40 days after results of Feb 25, 2026, 29 days before results of May 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +2.6% | +5.3% | −2.8% |
| 30 days | +7.2% | +11.0% | −3.8% |
| 90 days | +67.0% | +14.0% | +53.0% |
| 180 days | +29.5% | +17.5% | +12.0% |
Past results only. Not a forecast.
David Joseph Gaffin (EVP, CLO, Alkermes, Inc.) sold ~$68K of Alkermes plc
Scheduled in advanceTraded May 1 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Craig C. Hopkinson (EVP R&D, Chief Medical Officer) sold ~$301K of Alkermes plc
Scheduled in advance